While a suite of new CSF markers has entered a mature stage where they get validated with identical methods in large international cohorts, much newer blood tests are catching up fast. Scientists are pushing the limits of detection of the core AD markers in plasma, and in the process are cracking open what used to be considered the single category of p-tau into a bewildering new spectrum of subspecies.
Blood Tests of Phospho-Tau, Aβ42, Track With Brain Amyloid
View Content